NICE turns down GSK's IV Benlysta for systemic lupus

Pharma Times

4 June 2021 - NICE has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus.

The preliminary decision, outlined in an appraisal consultation document, relates to use of the drug in people aged five years and older when there is a high degree of disease activity (for example, positive anti-double-stranded DNA, low complement) and despite standard therapy, as per its marketing authorisation.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder